Saturday 17 October 2026
Export ACON’s income statement to Excel — free account
Aclarion, Inc.
ACON Healthcare Health Information Services
Aclarion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75,700.00, up 65.6% from fiscal 2024. In the quarter to June 2026, revenue grew 30.6%, EPS grew 59.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.85
0.10
−5.13%
Follow ACON
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
64.81 | 32.33 | 89.52 | 84.72 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.76) | (1.50) | (2.64) | (2.67) | |
P/B ratio |
0.35 | 0.19 | 0.35 | 0.42 | |
Price to Tangible BV |
0.39 | 0.21 | 0.38 | 0.45 | |
EV/Sales |
(100.17) | (123.47) | (151.91) | (107.19) | |
EV/EBITDA |
1.01 | 1.37 | 1.42 | 0.95 | |
EV/Operating CF |
1.05 | 1.30 | 1.62 | 1.11 | |
EV/FCF |
1.01 | 1.27 | 1.58 | 1.09 | |
Quick Ratio |
16.29 | 14.42 | 19.34 | 15.76 | |
Current Ratio |
17.01 | 14.81 | 19.65 | 16.20 | |
Net Debt/EBITDA |
6.41 | 6.23 | 6.50 | 5.75 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.00 | 0.01 | |
Operating CF/Net income |
0.68 | 0.86 | 0.93 | 0.97 | |
Capex/Depreciation |
(0.69) | (0.68) | (0.81) | (0.70) | |
Research and Development Expense of Revenue |
1,597.88% | 1,422.16% | 1,494.79% | 1,178.97% | |
Selling, General and Administrative Expense of Revenue |
8,112.70% | 9,360.54% | 12,679.15% | 10,360.71% | |
Intangible Assets out of Total Assets |
0.10 | 0.09 | 0.06 | 0.07 | |
Share Based Compensation of Revenue |
88.36% | 23.78% | 22.27% | 405.16% | |
Graham Net Nets |
2.57 | 4.72 | 2.64 | 2.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10,293.66%) | (369.78%) | (276.15%) | (256.94%) | |
Free Cash Flow Yield |
(152.99%) | (301.29%) | (107.33%) | (116.50%) | |
Revenue per Share |
0.03 | 0.03 | 0.01 | 0.01 | |
Operating CF per Share |
(1.99) | (3.06) | (1.24) | (1.08) | |
Capex per Share |
(0.07) | (0.08) | (0.02) | (0.02) | |
Free Cash Flow per Share |
(2.06) | (3.14) | (1.26) | (1.10) | |
Cash per Share |
19.52 | 22.63 | 8.93 | 6.62 | |
Shareholders Equity per Share |
21.46 | 24.13 | 9.23 | 6.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.46 | 24.13 | 9.23 | 6.91 | |
Free Cash Flow |
(1.20) | (1.67) | (2.69) | (2.70) | |
Working Capital |
11.21 | 11.56 | 18.39 | 15.76 | |
Capital Expenditures |
(0.04) | (0.04) | (0.05) | (0.04) | |
Net Current Asset Value |
11.21 | 11.56 | 18.39 | 15.76 | |
EV/EBIT |
0.98 | 1.33 | 1.38 | 0.92 | |
Capex to Sales |
2.12 | 2.24 | 2.34 | 1.71 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.02 | 0.03 | 0.02 | |
Average Payables |
0.30 | 0.43 | 0.55 | 0.49 | |
Average Assets |
8.19 | 7.90 | 18.56 | 16.40 | |
Average Common Equity |
7.51 | 6.90 | 17.72 | 15.60 |
Columns are period end dates